• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Nanobiotix S.A.

    5/12/25 11:35:02 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NBTX alert in real time by email
    6-K 1 f6k_051225.htm FORM 6-K
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 6-K

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of May 2025

    Commission File Number: 001-39777

    Nanobiotix S.A.
    (Translation of registrant's name into English)

    60 Rue de Wattignies 75012 Paris, France
    (Address of principal executive office)

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
    Form 20-F [ X ]      Form 40-F [   ]

     

     


    On May 12, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

    (c) Exhibit 99.1. Press release dated May 12, 2025


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

          Nanobiotix S.A.    
      (Registrant)
       
      
    Date: May 12, 2025     /s/ Bart Van Rhijn    
      Bart Van Rhijn
      Chief Financial Officer
      
    Get the next $NBTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NBTX

    DatePrice TargetRatingAnalyst
    8/28/2024$12.00Buy
    Guggenheim
    12/8/2023$11.00Outperform
    Leerink Partners
    More analyst ratings

    $NBTX
    Financials

    Live finance-specific insights

    See more
    • Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer

      Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancerMedian Overall Survival of 23 months from date of diagnosis [95% CI; 17 months – not reached]Median Local Progression-Free Survival of 13.3 months from completion of radiationNotable findings observed in exploratory biomarker analyses include: An association between increased circulating tumor mutational burden (cTMB) and LPFS and OSCA19-9 normalization in 59% of patients in the study, and an association between CA19-9 normalization and OS First patient injected in a new cohort that adds standard-of-care concurre

      5/5/25 2:00:00 AM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

      Full results from the completed dose escalation part and dose expansion parts of a Phase 1 study evaluating JNJ-1900 (NBTXR3) after induction chemotherapy for patients with locally advanced or borderline resectable pancreatic cancer to be presented by Principal Investigator Eugene Koay, MD, at ESTRO 2025 on Sunday, May 4th at 11:00 AM EDT / 5:00 PM CESTNanobiotix will host an event on Monday, May 5th at 8:00 AM EDT / 2:00 PM CEST to review the presented results PARIS and CAMBRIDGE, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expa

      4/30/25 2:00:00 AM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

      Global development program for JNJ-1900 (NBTXR3) proceeding as planned, with opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lung cancerDisciplined financial strategy toward long-term sustainability and growth continues to strengthen financial position through focused allocation of capital, the receipt of a planned milestone payment, the transfer of sponsorship for NANORAY-312, and an amendment to the global licensing agreement for JNJ-1900 (NBTXR3)Curadigm, a next generation nanotherapeutic platform designed to reshape drug design and development across multiple therapeutic classes and disease areas, has launchedCash r

      4/2/25 4:15:00 PM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Nanobiotix S.A. (Amendment)

      SC 13G/A - Nanobiotix S.A. (0001760854) (Subject)

      2/9/24 5:07:50 PM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Nanobiotix S.A. (Amendment)

      SC 13G/A - Nanobiotix S.A. (0001760854) (Subject)

      2/8/24 8:27:02 PM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Nanobiotix S.A. (Amendment)

      SC 13G/A - Nanobiotix S.A. (0001760854) (Subject)

      2/2/24 4:32:27 PM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBTX
    SEC Filings

    See more
    • SEC Form S-8 filed by Nanobiotix S.A.

      S-8 - Nanobiotix S.A. (0001760854) (Filer)

      5/14/25 4:37:40 PM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Nanobiotix S.A.

      6-K - Nanobiotix S.A. (0001760854) (Filer)

      5/14/25 6:00:07 AM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Nanobiotix S.A.

      6-K - Nanobiotix S.A. (0001760854) (Filer)

      5/12/25 11:35:02 AM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $NBTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Guggenheim initiated coverage on Nanobiotix with a new price target

      Guggenheim initiated coverage of Nanobiotix with a rating of Buy and set a new price target of $12.00

      8/28/24 7:51:18 AM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Nanobiotix with a new price target

      Leerink Partners initiated coverage of Nanobiotix with a rating of Outperform and set a new price target of $11.00

      12/8/23 8:52:29 AM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

      PARIS and CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conference: H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ Date: Tuesday, May 20, 2025Time: 5:00 pm EDT / 11:00 pm CESTLocation: New York, NYPresenters: Bart van Rhijn, Chief Financial & Business Officer of NanobiotixWebcast link: Click here The fireside chats will be webcast live from the eve

      5/12/25 2:00:00 AM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer

      Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancerMedian Overall Survival of 23 months from date of diagnosis [95% CI; 17 months – not reached]Median Local Progression-Free Survival of 13.3 months from completion of radiationNotable findings observed in exploratory biomarker analyses include: An association between increased circulating tumor mutational burden (cTMB) and LPFS and OSCA19-9 normalization in 59% of patients in the study, and an association between CA19-9 normalization and OS First patient injected in a new cohort that adds standard-of-care concurre

      5/5/25 2:00:00 AM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

      Full results from the completed dose escalation part and dose expansion parts of a Phase 1 study evaluating JNJ-1900 (NBTXR3) after induction chemotherapy for patients with locally advanced or borderline resectable pancreatic cancer to be presented by Principal Investigator Eugene Koay, MD, at ESTRO 2025 on Sunday, May 4th at 11:00 AM EDT / 5:00 PM CESTNanobiotix will host an event on Monday, May 5th at 8:00 AM EDT / 2:00 PM CEST to review the presented results PARIS and CAMBRIDGE, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expa

      4/30/25 2:00:00 AM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBTX
    Leadership Updates

    Live Leadership Updates

    See more
    • NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

      PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) --  NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will host a virtual KOL (Key Opinion Leader) event Tuesday June 18, 2024 at 9:00-10:30AM EDT / 3:00-4:30PM CEST. The event will feature several KOLs, including Study 1100 Coordinating Investigators Dr Colette Shen, MD, PhD and Dr Ari Rosenberg, MD, and Dr Jeffrey Bockman, PhD, will moderate the event. The KOLs will join Dr Sebastien Paris, PhD, from the Company to provide an in-depth review of NBTXR3 and the data recently presented at the

      6/12/24 4:15:00 PM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023

      PARIS and CAMBRIDGE, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will report its financial results for half-year ending June 30, 2023, on Tuesday, September 26, 2023, after the close of the US market. This release will be followed by a conference on Wednesday, September 27, 2023, at 8:00 AM EDT / 2:00 PM CEST. During the call, Laurent Levy, chief executive officer, and Bart van Rhijn, chief financial officer, will briefly review the Company's half-year results and provide an update on business activiti

      9/19/23 4:15:00 PM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer

      PARIS and CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the appointment of Louis Kayitalire, MD, as chief medical officer. Dr. Kayitalire brings an exceptional biopharmaceutical industry track record with proven success in the research, development, registration, and commercialization of therapeutics in oncology. "We are pleased to welcome Dr. Kayitalire to our executive leadership team at this pivotal moment for the development and commercialization of potential first-in-class radioenhancer NBTXR3," sa

      9/5/23 4:15:00 PM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care